SIRT6 Longevity: Mouse Lifespan, Human Evidence & What Is Proven

SIRT6 has unusually strong longevity evidence for a mammalian gene—but almost all causal lifespan evidence is still from mice. Genetic SIRT6 overexpression has extended mouse lifespan in two major experiments, comparative studies link stronger SIRT6 biology with longer-lived mammals, and late-life SIRT6 delivery can reverse selected age-associated chromatin changes in old mouse liver.

Human evidence is much earlier. SIRT6 levels and variants are associated with aging-related phenotypes, and direct SIRT6 activators have reached human trials, but no intervention has shown that increasing SIRT6 extends human lifespan or clinically validated healthspan.

Evidence layer	What it shows	What it does not show
Genetic mouse overexpression	Longer lifespan and healthier late-life physiology	That a drug or supplement reproduces the effect
Comparative mammal biology	SIRT6 repair/regulatory features correlate with species longevity	Human intervention benefit
Late-life mouse gene delivery	Selected chromatin-aging features can shift toward a younger pattern	Whole-body rejuvenation or longer life
Human observational/genetic studies	SIRT6 is associated with aging, frailty and rare longevity biology	That low SIRT6 causes aging or treatment reverses it
Human activator trials	SIRT6 can be pharmacologically targeted in people	Anti-aging or lifespan efficacy

Kanfi 2012: the first SIRT6 lifespan experiment

The foundational lifespan study genetically overexpressed SIRT6 in mice from early life. Male transgenic mice lived longer than wild-type controls, with median lifespan increases of approximately 14.5% and 9.9% in two independent transgenic lines [1].

The effect was sex-specific in that experiment: female lifespan was not significantly extended. Metabolic and IGF-related changes were part of the phenotype, but the central result was genetic rather than pharmacological. These animals did not begin a SIRT6 intervention in middle age; they carried increased SIRT6 expression throughout life.

That distinction is fundamental. A gene-overexpression lifespan experiment establishes target biology. It does not establish a supplement dose.

Roichman 2021: lifespan extension in both sexes

A later study strengthened the longevity case substantially. SIRT6 overexpression increased median lifespan by about 27% in males and 15% in females in that model and improved multiple late-life physiological measures [2].

The paper linked SIRT6 longevity to improved energy homeostasis, preservation of metabolic function and changes in IGF-1 signaling. This corrected the idea that SIRT6 lifespan extension had only ever been observed in males.

It did not solve the translational problem: this was still genetic overexpression, not treatment of ordinary adults with a SIRT6-activating compound.

Why comparative biology makes the target more interesting

Longevity genes are more persuasive when the same biology appears across species rather than in one engineered mouse strain.

In 2019, researchers compared SIRT6 from 18 rodent species and found that SIRT6 from longer-lived species was more effective at supporting DNA double-strand-break repair [3]. Specific amino-acid differences helped explain the activity gap.

A 2026 comparative study added another layer: longer-lived mammals had more SIRT6 C-terminal phosphorylation sites and greater use of those sites. Hyperphosphorylated SIRT6 interacted more strongly with PARP1, and a phospho-mimetic T294E mutation improved oxidative-stress resistance in human fibroblasts [4].

These studies support evolutionary tuning of SIRT6-associated genome maintenance. They do not prove that pharmacological activation in an adult human reproduces the evolutionary phenotype.

Can increasing SIRT6 late in life reverse aging biology?

This question is more clinically relevant than lifelong transgenic overexpression. A 2026 Nature Communications study delivered SIRT6 to the livers of already-aged male mice using an AAV vector [5].

The intervention shifted multiple age-associated chromatin-accessibility and transcriptional patterns toward younger profiles, including inflammatory and metabolic programs. The result is important because treatment began late rather than at conception.

But “reversed aging” is too broad. The study examined liver molecular phenotypes; it did not demonstrate whole-body rejuvenation, lifespan extension after late-life treatment or equivalent effects in people.

SIRT6, one-carbon metabolism and caloric-restriction biology

A 2025 study linked SIRT6 overexpression with one-carbon metabolism, hydrogen-sulfide signaling and age-related metabolic regulation in mouse liver [6].

This provides a mechanistic connection between SIRT6 and pathways also influenced by dietary restriction. It should not be described as evidence that SIRT6 “mimics caloric restriction” in humans. Dietary-restriction longevity effects vary by species, sex, strain, nutritional composition and endpoint, and primate evidence is more complex than a universal lifespan-extension claim.

What do human studies actually show?

The human case is currently made of associations, genetics and target-development evidence—not longevity intervention outcomes.

Centenarian genetics

A rare centenarian-associated SIRT6 variant identified in Ashkenazi Jewish centenarians showed enhanced genome-stability functions in laboratory experiments [7]. The biological effect of the variant is interesting; the small genetic cohort limits population-level inference.

Serum SIRT6 and age

Cross-sectional human work has reported lower serum SIRT6 with older age [8]. Another older-adult cohort found lower serum SIRT6 associated with frailty [9].

These are observational biomarkers. Serum SIRT6 is not an established clinical aging test, and an association between low SIRT6 and frailty does not prove that treatment will reverse frailty.

What about fucoidan and mouse lifespan?

A 2025 bioRxiv preprint reported that dietary fucoidan beginning at 15 months of age increased median lifespan by about 13% in male mice; the approximately 3% female increase was not statistically significant [10].

The study included SIRT6-dependent mechanistic experiments and used DoNotAge-supplied Fucus vesiculosus fucoidan for the in-vivo aging cohort. That makes it commercially relevant. It is still a preprint, uses mouse exposures far above consumer mg/kg dosing, and has not demonstrated human lifespan or healthspan benefit.

Have SIRT6 activators reached human trials?

Yes—but not with a positive human longevity result.

The synthetic SIRT6 activator forvisirvat/SP-624 has published Phase 1 safety/pharmacokinetic data [11] and a published 319-person Phase 2 major-depression trial [12]. The Phase 2 study did not significantly outperform placebo on its prespecified primary endpoint overall.

That program proves that a direct SIRT6 activator can be developed and administered to humans. It does not prove geroprotective efficacy.

Fucoidan-based human healthy-aging research is also underway. The PROMETHEUS protocol includes SIRT6Activator as part of a multimodal program [13], while Project SIRT6 Activator is directly randomizing 2.4 g/day fucoidan against placebo with biological-age endpoints.

See SIRT6 clinical trials for current trial status.

What would count as convincing human longevity evidence?

A useful human study would need more than an increase in circulating SIRT6 or a single epigenetic clock. Ideally it would show target engagement plus replicated improvement in validated aging-related outcomes such as physical function, multimorbidity, clinically meaningful biomarkers or long-term disease events.

Lifespan itself requires very long follow-up. For that reason, early geroscience trials often use intermediate outcomes. Those endpoints can be useful, but they should not be described as proof of longer life.

What the newest 2026 studies change

A Ser10 phosphorylation preprint complicates the idea that stronger DNA repair is automatically pro-longevity. A phosphomimetic SIRT6 S10E mutation improved repair but increased LINE1 expression and shortened male lifespan compared with wild-type and S10A mice [14]. This is preprint-level mouse genetics, but it is an important functional-balance experiment: repair, retrotransposon repression and lifespan can move in different directions.

A separate peer-reviewed 2026 study found strong sex and tissue specificity. Hepatocyte-specific SIRT6 loss shortened median lifespan by 17.6% in female mice while aged males developed a different compensatory metabolic phenotype. In aged females, MDL-800 improved several estrogen-linked and gerometabolic abnormalities [15]. This does not establish a female human anti-aging indication; it strengthens the case that sex and tissue context should be designed into future SIRT6 trials.

Bottom line

SIRT6 is one of the more credible mammalian longevity targets because lifespan extension has been reproduced genetically in mice and its genome-maintenance biology tracks with species longevity. Late-life gene delivery and modern pharmacology make the target more translationally interesting than it was a decade ago.

The missing link remains human geroscience efficacy. No SIRT6 activator has yet demonstrated longer human lifespan or clinically validated healthspan.

For mechanism, see SIRT6 mechanism and structure. For DNA repair, see SIRT6 DNA repair. For the ingredient-specific mouse data, see fucoidan and SIRT6.